Aurobindo Pharma, India’s fourth largest drug maker – known to have the lowest R&D spends vis-à-vis sales among its peer group is bracing up for higher spends as it plans to develop biosimilar drugs that require testing on humans to establish safety, efficacy, and similarity with the innovator drug. The company on Friday said it plans to spend about USD 80 million in next two years as it prepares to take the lead biosimilar molecule bevacizumab into the clinical trial. The company expects to begin the trial this year and set a target of the regulatory filing in Europe by 2020.
Bevacizumab is a biosimilar version of Roche’s Avastin, a monoclonal antibody used in the treatment of multiple cancers. Aurobindo on Thursday announced an acquisition of four under development biosimilar products including Bevacizumab from Switzerland-based TL Biopharmaceutical. The company didn’t close the deal size but said it will develop, commercialize and market these products globally. In addition to TL Biopharmaceutical’s four products – Aurobindo is also developing eight other biosimilars on its own targeting therapeutic segments such as oncology, rheumatology, ophthalmology and respiratory.
Get live News Updates visit us at http://www.ripplesadvisory.com/nifty-future-.php or One Missed Call on @9303-093093
No comments:
Post a Comment